

Strides gets EIR from USFDA on continued GMP status

25 July 2019 | News

Recently the company communicated that the inspection of the facility was completed successfully with a Voluntary Action Indicated (VAI) classification



Strides Pharma Science has announced that its formulations facility located at the KRSG Gardens, in Bengaluru was which was inspected by the US FDA in May 2019, has received the Establishment Inspection Report (EIR).

The Bengaluru- based company confirms the successful closure of the inspections by the regulatory authority.

Early this week the company communicated that the inspection of the facility was completed successfully with a Voluntary Action Indicated (VAI) classification. This production plant according to Strides is the largest manufacturing facility for it with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids.

The products manufactured in India are exported to the key regulated markets of the US, Europe, and Australia.